Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Adult mouse liver stained with antibodies to the surface markers CD26 (green) and 2G9 (red). Azuma et al. describe a mouse model that allows engraftment and expansion of human hepatocytes. p 903.
The example set by leading proteomics laboratories will be a major factor in determining the successful implementation of new reporting guidelines in the wider community.
Despite hand-wringing over the patenting of a minimized organism, both patents and open-source approaches will be needed to promote innovation and research progress in synthetic biology.
When Zheng Xiaoyu took the helm of the Chinese State Food and Drug Administration (SFDA) nine years ago, hopes were high for effective regulatory oversight of China's drug industry. Now those hopes have been dashed with tragic personal consequences for Zheng and allegations of widespread corruption by Chinese officials.
An analysis of recent returns from venture-backed biotech firms reveals that companies receiving the most financing do not necessarily deliver the best returns.
As the cost of drug development continues to rise and public markets shift their attention to companies with late-stage products, an increasing diversity of financing options are becoming available to biotech companies with early-stage clinical programs.
Computational prediction of gene structure is crucial for interpreting genomic sequences. But how do the algorithms involved work and how accurate are they?
In the drug discovery industry, the key to managing innovation is to make the best use of scientists' creativity and build an innovation-fostering culture.